Skip to main content
Premium Trial:

Request an Annual Quote

Pillar Biosciences, China Biotech Services Form Joint Venture

NEW YORK (GenomeWeb) – Pillar Biosciences announced a strategic partnership and joint venture with China Biotech Services Holdings today that is aimed at the precision diagnostics market in Asia.

Pillar Bio will create a JV with Central Laboratory, a subsidiary of China Biotech Services, to provide precision diagnostic products and services to Hong Kong, Macau, South Korea, and Southeast Asia. Additionally, the JV will distribute Pillar Bio's products, including the SLIMamp and Pivat-based cancer panels, in parts of China.

China Biotech Services will also participate in Pillar Bio's Series B financing round, which initially closed in November.

Financial and other terms of the deal were not disclosed.

Pillar Bio is based in Boston and Shanghai and develops clinical cancer diagnostics, including next-generation sequencing-based panels and software solutions. In late 2017, the company partnered with Illumina to develop NGS-based in vitro diagnostics.

Hong Kong-based China Biotech Services is a clinical testing company with a third-party pathology testing laboratory.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.